Home > News > Latest > HealthWorksAI™ Unveils the First Healthcare Data Platform using xAI technology

Healthcare Analytics

HealthWorksAI™ Unveils the First Healthcare Data Platform using xAI technology

HealthWorksAI™, an industry-leading Healthcare analytics company, announces the launch of the 2nd generation of their state-of-the-art xAI program. It's an advanced analytical approach that collects and processes data, generating in-depth market analysis which standard models do not uncover. Allowing data scientists an efficient way to measure the impact of various plan attributes/factors, xAI provides a better understanding of the correlation between plan features and beneficiary preference. It also provides insights into the influence of multiple verticals at the market level. The models are then combined with the human-computer interface (HCI) features capable of translating models into practical explanations for end users.

"We use a combination of Rule-based algorithms, Random Forest, and Artificial Neural Networks to develop our proprietary prediction, classification, and performance metrics," says Shreya, Data Scientist of HealthWorksAI™. "Advanced analytics & xAI comes to play in the modeling and evaluation phases of data mining. To achieve this, we use LIME and DeepLIFT, as an example, to achieve far superior results."The xAI program, released in early 2021, has been a huge success for HealthWorksAI, leading as their most subscribed platform module in its first year. The 2nd generation, which will see releases begin in early Q2, includes multiple platform enhancements as well as new approaches to xAI methodologies.

"We're excited to announce the expansion of our xAI program for MA Payors. One of the defining aspects of our company is the partnership our clients provide. We appreciate their faith and confidence and look forward to delivering even more for them in 2022!"

Jereme Ayers, Chief Growth Officer of HealthWorksAI

About HealthWorksAI

HealthWorksAI™ is a privately held healthcare data analytics company in the US that provides healthcare payors with rapid access to very efficient and insightful Medicare Advantage market data, accurate predictions, and a reliable single source of truth for strategic decision-making.

It is the only company in the industry to accurately predict the enrollments for all the health plans down to the county level within 72 hours of the CMS' (Center for Medicare and Medicaid Services) big reveal on October 1st every year.

Spotlight

Other News

Digital Healthcare

ClosedLoop Introduces Data Science Products for Value-Based Healthcare

ClosedLoop | September 20, 2023

ClosedLoop, a prominent healthcare data science platform, has formally introduced two novel data science solutions. These solutions, namely, ACO-Predict and Evaluate, are crafted to assist healthcare organizations in the comprehensive analysis, assessment, ongoing surveillance, and enhancement of their programs, with the objectives of minimizing adverse events, enhancing health outcomes, and curtailing expenditures. ClosedLoop's offering, ACO-Predict, marks the healthcare sector's inaugural no-cost AI-powered solution for population health risk stratification. It harnesses the same algorithms that propelled ClosedLoop to garner fame in the 2021 CMS AI Challenge and earned the Best in KLAS Healthcare AI ranking for 2022 and 2023. When integrated with the updated Beneficiary Claims Data API data feeds from the Centers for Medicare and Medicaid Services, the product furnishes Medicare Accountable Care Organizations with a turnkey risk stratification tool for Complex Care Management programs, all free of charge. Meanwhile, the company's second product, ClosedLoop Evaluate, is a SaaS solution designed to evaluate and continuously monitor the efficacy of intricate population health initiatives over extended durations. Quantifying the impact and ROI of Population Health programs has presented significant challenges. Organizations often need to resort to imprecise pre- and post-assessments or enlist costly consulting firms for one-off outcome research studies to understand the actual effects of their programs. ClosedLoop’s solutions aim to improve healthcare organizations' outcomes and offer essential patient support. Jennifer Zbell, VP of Clinical Analytics at Healthfirst, stated, ClosedLoop provided the quantitative evidence we needed to increase investment in successful programs." She added, "Evaluate gives us the confidence to examine our programs across the board so we can better see what's working, when it's working, and who it's working for. [Source – Business Wire] ClosedLoop Evaluate represents a pioneering industry solution that not only supplants these studies with software-driven evaluations but also facilitates the ongoing assessment of program impact amid evolving programs and populations. Andrew Eye, Co-Founder and CEO of ClosedLoop concluded that success in value-based care hinges on two key aspects: accurate prediction and effective intervention. ACO-Predict delivers AI-powered prediction capabilities to all medicare patients nationwide at no cost, ensuring access to necessary assistance regardless of location or ACO resources. About ClosedLoop ClosedLoop is a dedicated data science platform tailored to the healthcare sector, simplifying the integration of AI technology to enhance outcomes and curtail expenses. Uniquely designed for the healthcare domain, the company merges an intuitive, all-encompassing ML platform with an extensive repository of healthcare-specific functionalities and model templates. Customers leverage ClosedLoop's Explainable AI capabilities to facilitate clinical excellence, streamline operational processes, navigate value-based contracts, and bolster revenue generation in the healthcare industry.

Healthcare Analytics

FDA Grants De Novo for Xenex's LightStrike+ UV Robot in Healthcare

Xenex | September 11, 2023

United States Food and Drug Administration (USFDA) has issued a De Novo authorization to Xenex Disinfection Services, Inc. (Xenex) for its LightStrikeTM+ device, an advanced high-intensity, broad-spectrum ultraviolet (UV) light robot. The LightStrike+ devices are designed for microbial reduction on non-critical medical device surfaces in healthcare environments, following manual cleaning and disinfection practices. They are authorized for use in various healthcare settings, including unoccupied operating rooms and hospital rooms. These devices have an impressive track record, with over 1,200 healthcare facilities worldwide employing LightStrike robots for over 37 million cycles. The new LightStrike+ device, capable of microbial reduction in as little as 2 minutes, represents the culmination of over a decade of knowledge accumulation from healthcare facilities' best practices, supported by 45 peer-reviewed studies demonstrating its safety and effectiveness, a portfolio of 193 patents, and unparalleled technical and epidemiological expertise. Dr. Mark 'Tuck' Stibich, Xenex's Founder and Chief Scientific Officer, emphasized the long-standing collaboration with healthcare partners spanning more than a decade to enhance patient safety and public health. As an infectious diseases epidemiologist, Dr. Stibich expressed concern about antibiotic resistance within hospital environments and the potential for FDA authorization to facilitate the broader adoption of the LightStrike+ tool in combating pathogens. Perilous pathogens persist on surfaces within healthcare facilities, notwithstanding diligent manual cleaning endeavors. The LightStrike+ robot employs a xenon lamp to generate high-intensity pulsed UV light, which effectively diminishes the presence of these pathogens on surfaces and plays a pivotal role in interrupting the transmission chain from one patient or healthcare worker to another. Xenex's FDA authorization is substantiated by comprehensive testing conducted on more than 10,000 samples of vegetative bacteria and Clostridiodes difficile (C. diff) spores. This authorization establishes a novel medical device product classification, with the LightStrike+ robot being its inaugural and sole product. It is a landmark in the FDA's regulatory framework for UV robots designed to diminish pathogens on non-porous, frequently touched surfaces within healthcare settings. Furthermore, Xenex's Chief Executive Officer, Morris Miller, acknowledged the challenges hospitals face when evaluating UV technologies, citing the prevalence of unverified and exaggerated claims by some manufacturers. He underscored the significance of FDA authorization in instilling confidence among hospital decision-makers, assuring them of the accuracy and validation of Xenex's claims regarding the LightStrike+ device. Numerous world-renowned hospitals, such as HonorHealth, Mayo Clinic, MD Anderson Cancer Center, Ochsner Health System, Stanford Health Care, and Texas Health Resources, have integrated LightStrike robots into their comprehensive disinfection strategies. About Xenex Xenex is a global leader in pioneering strategies and solutions grounded in UV technology. Its fundamental mission revolves around enabling its partners to safeguard lives and reduce human suffering by eliminating the dangerous microorganisms that cause infections. The company benefits from substantial support from renowned investors, including EW Healthcare Partners, Piper Sandler, Malin Corporation, Battery Ventures, Targeted Technology Fund II, Tectonic Ventures, and RK Ventures.

Healthcare Analytics

Weave Introduces AI-Driven Voicemail Transcriptions for Healthcare Providers

Business Wire | October 31, 2023

Weave a leading all-in-one experience platform for small and medium-sized healthcare practices, today announces the addition of AI-driven voicemail transcriptions to its platform. Now available to Weave’s 27,000+ customers, Voicemail Transcription automatically transcribes voicemails from patients allowing for efficient, visible, and private reading experiences. With this update, users will now see the voicemail transcription when they click on the Voicemail tab within their Desktop Application or within the mobile app, improving overall user experience by making it faster to consume messages without having to listen to the audio, which can often be difficult in busy settings. said Branden Neish, Chief Product and Technology Officer at Weave. AI has exploded in popularity over the past year, and we’re taking steps to ensure Weave is delivering state of the art offerings that empower our customers to enhance patient experiences and deliver top of the line care. AI will only continue to grow in popularity and daily use, which will have a transformative impact on the future of the healthcare industry. Weave customers that have already implemented AI into their practices claim they save an average of an hour a day with the technology. [Source:Business Wire] In a new customer and consumer report conducted by Weave, the company found that patients are accepting of AI in healthcare settings and they see it leading to enhanced care and patient experiences. In fact, the majority of consumers (65%) are open to providers using AI tools in their practices. The report also found that consumers and providers are aligned with how they think AI will impact the healthcare industry, with two in three consumers (67%) and 3 in 4 (75%) healthcare providers believing that AI is likely to become a prevalent tool in healthcare. "Artificial Intelligence is the catalyst for a new era in healthcare,” says Dr. Matt Nejad, DDS of Beverly Hills, CA. “Weave's AI-enabled voicemail transcripts are a leap in this direction, providing automation and actionable insights that empower providers to focus on what truly matters: patient care." This announcement follows months of AI-driven activity from Weave to enhance features that allow healthcare providers to deliver quality care and improve patient experiences, including Email Assistant and Response Assistant. About Weave Weave is a leading all-in-one customer experience platform for small- and medium-sized healthcare businesses. From the first phone call to the final invoice and every touchpoint in between, Weave connects the entire customer journey. Weave’s software solutions transform how local businesses attract, communicate with and engage customers to grow their business. In the past year, Weave has been named a G2 leader in Patient Engagement, Optometry, Dental Practice Management and Patient Relationship Management software.

Healthcare Analytics

AirLife Completes Acquisition of Avanos Medical’s Respiratory Health Business

Business Wire | October 04, 2023

AirLife, a leading North American manufacturer and distributor of consumable medical devices for anesthesia and respiratory care formerly known as SunMed, today announced the completion of its acquisition of Avanos Medical, Inc.’s (NYSE: AVNS) (“Avanos”) respiratory health business, including the BALLARD*, MICROCUFF* and endOclear® product lines. The acquisition adds three complementary brands, the R&D expertise behind them and two manufacturing facilities into AirLife’s growing platform. The transaction advances AirLife’s strategy to enhance its leading portfolio of the most trusted products in anesthesia and respiratory care and serve even more customers as a one-stop source for the highest-quality consumable breathing solutions that support the best patient outcomes. “We’re thrilled to complete this exciting milestone in AirLife’s evolution as we strengthen our leadership as a premier, completely dedicated consumable breathing products company,” said Hank Struik, AirLife CEO. We are especially pleased to welcome the exceptional team that has driven the success of these market leading brands to our company. As some of the most trusted closed suction and endotracheal consumables used to treat patients in critical care, this addition to AirLife unlocks new opportunities to accelerate our growth, serve more healthcare practitioners and drive innovation across our comprehensive portfolio of leading brands. [Source – Business Wire] Goodwin Procter LLP is acting as legal counsel to AirLife. About AirLife AirLife, formerly known as SunMed and headquartered in Grand Rapids, Michigan with manufacturing and distribution sites in the United States, Mexico, China and Europe, is a leading medical device manufacturer, offering one of the most comprehensive portfolios of consumable anesthesia and respiratory care products. AirLife’s product portfolio spans the continuum of care from first responders to hospitals and home care, with safety, patient comfort and clinical performance in mind. AirLife’s comprehensive portfolio of trusted anesthesia products and respiratory care include premier brands such as Salter Labs®, Ethox Medical™, Ventlab™, Westmed™, AirLife™ and Vital Signs™. Currently, AirLife has over 1 million square feet of manufacturing space, providing comprehensive expertise in all plastics materials and conversion—supported by a world-class Quality Management System. Frazier Healthcare Partners, a leading healthcare investment firm, acquired a majority ownership stake in AirLife in 2021.